Pulmonx Corporation
LUNG
$7.32
$0.020.27%
| Weiss Ratings | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.53 | |||
| Price History | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -11.70% | |||
| 30-Day Total Return | 20.99% | |||
| 60-Day Total Return | 14.55% | |||
| 90-Day Total Return | 8.12% | |||
| Year to Date Total Return | 12.27% | |||
| 1-Year Total Return | -17.75% | |||
| 2-Year Total Return | -34.47% | |||
| 3-Year Total Return | -65.36% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -27.07% | |||
| 52-Week Low % Change | 33.70% | |||
| Price | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.01 | |||
| 52-Week Low Price | $5.46 | |||
| 52-Week Low Price (Date) | Aug 12, 2024 | |||
| 52-Week High Price (Date) | May 06, 2024 | |||
| Valuation | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 290.51M | |||
| Enterprise Value | 245.50M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.44 | |||
| Earnings Per Share Growth | -10.02% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.45 | |||
| Price/Book (Q) | 3.38 | |||
| Enterprise Value/Revenue (TTM) | 2.93 | |||
| Price | $7.32 | |||
| Enterprise Value/EBITDA (TTM) | -4.43 | |||
| Enterprise Value/EBIT | -4.25 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 39.58M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 364 0400 | |||
| Address | 700 Chesapeake Drive Redwood City, CA 94063 | |||
| Website | pulmonx.com | |||
| Country | United States | |||
| Year Founded | 1995 | |||
| Profitability | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -68.86% | |||
| Profit Margin | -67.30% | |||
| Management Effectiveness | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -21.18% | |||
| Return on Equity | -- | |||
| Income Statement | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 83.79M | |||
| Total Revenue (TTM) | 83.79M | |||
| Revenue Per Share | $2.12 | |||
| Gross Profit (TTM) | 62.00M | |||
| EBITDA (TTM) | -55.39M | |||
| EBIT (TTM) | -57.70M | |||
| Net Income (TTM) | -56.39M | |||
| Net Income Avl. to Common (TTM) | -56.39M | |||
| Total Revenue Growth (Q YOY) | 23.28% | |||
| Earnings Growth (Q YOY) | 5.13% | |||
| EPS Diluted (TTM) | -1.44 | |||
| EPS Diluted Growth (Q YOY) | 8.01% | |||
| Balance Sheet | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 101.48M | |||
| Cash Per Share (Q) | $2.56 | |||
| Total Current Assets (Q) | 136.25M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 85.81M | |||
| Current Ratio (Q) | 5.575 | |||
| Book Value Per Share (Q) | $2.16 | |||
| Total Assets (Q) | 162.85M | |||
| Total Current Liabilities (Q) | 24.44M | |||
| Total Debt (Q) | 56.47M | |||
| Total Liabilities (Q) | 77.04M | |||
| Total Common Equity (Q) | 85.81M | |||
| Cash Flow | LUNG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 17.48M | |||
| Cash from Financing (TTM) | 1.36M | |||
| Net Change in Cash (TTM) | -12.62M | |||
| Levered Free Cash Flow (TTM) | -12.38M | |||
| Cash from Operations (TTM) | -31.54M | |||
